Germany Cancels Confidential Drug Pricing
Executive Summary
Plans to make pharmaceutical prices in Germany confidential are likely to be shelved, but other measures could help companies better navigate price transparency.
You may also be interested in...
How Broad Labels May Make Market Access In Germany More Difficult
Companies might have to rethink their German market access strategies if new legislation is passed to informs doctors of the outcome of AMNOG benefit assessments.
Germany May Make Drug Prices Confidential In AMNOG Update
Under forthcoming changes to the law, companies could gain confidential pricing in Germany, which could make it easier to defend a higher price in other countries. But sponsor of some orphan products may face a rockier path to market.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.